Breast cancer bone metastases often cause a debilitating non-curable condition with osteolytic lesions, muscle weakness and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery and anti-resorptive drugs that restrict but do not revert bone destruction. In metastatic breast cancer cells, we determined the expression of sclerostin, a soluble Wnt inhibitor that represses osteoblast differentiation and bone formation. In mice with breast cancer bone metastases, pharmacological inhibition of sclerostin using an anti-sclerostin antibody (Scl-Ab) reduced metastases without tumor cell dissemination to other distant sites. Sclerostin inhibition prevented the cancer-induced bone destruction by augmenting osteoblast-mediated bone formation and reducing osteoclastdependent bone resorption. During advanced disease, NF-kB and p38 signaling was increased in muscles in a TGF-b1-dependent manner, causing muscle fiber atrophy, muscle weakness and tissue regeneration with an increase in Pax7-positive satellite cells. Scl-Ab treatment restored NF-kB and p38 signaling, the abundance of Pax7-positive cells and ultimately muscle function. These effects improved the overall health condition and expanded the life span of cancer-bearing mice. Together, these results demonstrate that pharmacological inhibition of sclerostin reduces bone metastatic burden and muscle weakness with a prolongation of the survival time. This might provide novel options for treating musculoskeletal complications in breast cancer patients.
Introduction
Breast cancer is the most common cancer in women worldwide with a prediction to further increase in the future, representing a tremendous medical and socio-economic burden (1) . After treatment of the primary tumor, metastases often occur years or even decades later (1) . Bone is a premier site for breast cancer metastases and about 70% of breast cancer patients with advanced disease suffer from osteolytic bone metastases, a stage at which the disease is incurable (2) . Osteolytic metastases often cause skeletal-related events (SREs), including pathological fractures and pain that require palliative interventions (3, 4) .
Destruction of the bone tissue in breast cancer-induced osteolytic disease occurs due to an increased number and activity of bone-resorbing osteoclasts (5) . Osteoclasts are activated in a direct or indirect manner by cancer-and micro-environment-derived cytokines including parathyroid hormone-related peptide (PTHrP), receptor activator of NF-κB ligand (RANKL) and interleukins. Upon activation of bone resorption, matrix-derived growth factors and in particular transforming growth factor beta (TGF-β) further enhance tumor growth and osteoclast activity, constituting a 'vicious cycle' of bone metastasis (5) . While it is firmly established that breast cancer cell-and matrix-derived growth factors stimulate osteoclast activity, evidence exists that breast cancer cells also provide molecular cues that suppress osteoblast function (6) . Thus, it can be hypothesized that restoring osteoblast function might ameliorate metastatic bone disease.
Nevertheless, the exact role of bone-forming osteoblasts in the context of breast cancer metastasesmediated bone destruction and their potential use for pharmacological treatment is not yet elucidated.
In addition to chemotherapy and radiation therapy, patients with osteolytic metastases are treated with anti-resorptive drugs such as bisphosphonates or an antibody against RANKL (Denosumab; XGEVA ® , Amgen) that efficiently restrict osteoclast activity and therefore the 4 progression of bone destruction (7) . Due to advances in surgery, adjuvant chemotherapy, hormone receptor blocking drugs and anti-resorptive therapies, the survival time of patients has been greatly prolonged (8) . However, the overall morbidity and mortality are still very high, particularly once SREs occur (8) . Furthermore, the disease remains irreversible and osteolytic lesions persist (8) .
Since anti-resorptive drugs cannot revert osteolytic lesions, augmenting osteoblast function has been proposed as a potential approach to restore bone integrity in the context of metastasesinduced osteolytic lesions (9) . To date, only two bone anabolic drugs are available in the clinics for the treatment of osteoporosis, a debilitating disease that leads to loss of bone mass and ultimately fragility fractures. An intermittent administration of a recombinant fragment of osteoblast-mediated bone formation and bone mass but are not approved for use in cancer patients (6) . Thus, there is currently no osteoblast-targeting drug available in the US or in Europe that could be used for the treatment of cancer-related bone disease.
Osteoblast differentiation and function is regulated by a network of transcription factors and signaling pathways (10) . Canonical Wnt signaling is among the most prominent pathways promoting osteoblast differentiation, function and bone formation (11) . Activation of the canonical Wnt pathway occurs upon binding of Wnt ligands to low-density lipoprotein receptor-related protein 5 and 6 (Lrp5/6) that form a complex with frizzled-related proteins. Sclerostin is a soluble Wnt antagonist that prevents binding of Wnt ligands to Lrp5/6 and therefore the activation of the pathway and ultimately osteoblast-mediated bone formation (11) . Due to its strong inhibitory effect of Wnt signaling and pharmacological accessibility, sclerostin has emerged as a promising drug target and anti-sclerostin antibodies (Scl-Ab) have been developed to increase bone formation and bone mineral density (BMD) in the context of postmenopausal osteoporosis (12, 13) . In clinical trials, treatment of women with postmenopausal osteoporosis, Scl-Ab (Romosozumab; Evenity ® , Amgen/UCB) increased bone formation while bone resorption was decreased, leading to an increase in BMD and a reduction of the fracture rate at several sites including the hip and spine (13, 14) . Recently, Romosozumab has been approved in Japan for the treatment of severe postmenopausal osteoporosis and is expected to become available in the US and in Europe later this year. Thus far, activation of the canonical Wnt signaling pathway in the skeleton, neither in preclinical animal models nor by genetic or pharmacological means in humans, has caused any malignant side effect, demonstrating the overall safety of this approach in the musculoskeletal system. The strong effect of Wnt activation on increasing BMD and decreasing the fracture rate is also of interest in the context of bone fragility syndromes other than osteoporosis. For instance, osteogenesis imperfecta (OI) is often caused by mutations in the gene encoding collagen type 1, leading to brittle bones and fractures (15) . In this context, another Scl-Ab (BPS-804, Setrusumab, Mereo BioPharma) is currently been investigated in clinical trials for the treatment of patients with OI (16).
In breast cancer patients, SREs are often associated with muscle weakness, a debilitating condition that decreases mobility, well-being and life quality of breast cancer patients (17, 18) . The disease mechanisms underlying cancer-associated muscle weakness are largely unknown and no therapy is available to date (17, 18) . Thus, novel therapeutic approaches targeting breast cancer bone metastases and muscle weakness are urgently needed.
Here we report that metastatic breast cancer cells secrete sclerostin, thereby inhibiting canonical Wnt signaling in osteoblasts and osteoblast differentiation, indicating that breast cancer cells might impair bone formation while promoting metastases and bone resorption. Treatment of bone metastases-bearing female mice with Scl-Ab (Setrusumab) alleviated tumor growth in bone and bone destruction without increasing metastases at other sites. Surprisingly, Scl-Ab treatment protected from cancer-induced muscle fiber atrophy and loss of muscle function in tumor-bearing mice and prolonged the life span of these animals. These findings reveal that therapeutic inhibition of sclerostin reduces breast cancer-induced bone metastases and muscle weakness in mice, indicating its potential as novel therapeutic option for breast cancer patients. Figure 1D ). To determine whether sclerostin expression is a general feature of breast cancer cells, we performed an in silico analysis using the EMBL-EBI Expression Atlas (20) . In addition is also expressed by other types of cancer, we analyzed sclerostin expression in human colon (n=9), kidney (n=9), liver (n=9), lung (n=9), prostate (n=9), ovary (n=9) and thyroid (n=9) cancer biopsies and the respective healthy tissue. Sclerostin expression was detected in two colon (22%), one ovary (11%) and two lung (22%) cancer tissues, suggesting that although sclerostin expression is not specific to breast cancer, it is not a general oncogenic feature of all types of cancer (Table 1) .
Results

Breast cancer cell-derived sclerostin inhibits Wnt signaling in osteoblasts
To investigate whether breast cancer cell-derived sclerostin reduces Wnt signaling activity in osteoblasts, we restricted sclerostin expression in MDA-MB-231 cells using three different siRNAs designed to target SOST mRNA (Supplemental Figure 1A Heterozygous missense mutations (G171V and A214V) within this domain of LRP5 cause a high bone mass phenotype in patients and in mice due to a reduced binding of sclerostin (25, 26) . To determine whether cancer cell-derived sclerostin inhibits Wnt activity in osteoblasts through Lrp5, we obtained osteoblasts from genetically modified mice heterozygous for the Lrp5 mutation G171V. In support of our hypothesis, osteoblasts bearing a mutant Lrp5 with a disabled sclerostin binding site were resistant to breast cancer-mediated repression of Wnt signaling ( Figure 1G ).
These data suggest that breast cancer cells impair osteoblast differentiation, at least in part, by a sclerostin/Lrp5-mediated inhibition of the canonical Wnt signaling pathway.
Pharmacological inhibition of sclerostin reduces the bone metastatic burden and prolongs the survival time
Given the negative effect of cancer-derived sclerostin on osteoblasts, we hypothesized that 
Sclerostin antibody treatment protects from breast cancer-induced bone destruction
To test the hypothesis that inhibition of sclerostin might be a therapeutic approach to prevent bone destruction or to restore bone integrity in the context of breast cancer-mediated bone destruction, bone mass of mice with and without bone metastases was quantified by micro-computed tomography (CT). Consistent with previous reports (27) To further analyze the mode of action of Scl-Ab in mice with breast cancer bone metastases, amino pro-peptide of type 1 collagen (P1NP) and Tartrate-resistant acid phosphatase (TRAP) 5b
were measured in the serum of cancer-bearing mice as biomarkers for bone formation and bone resorption, respectively. While the P1NP serum concentration was higher in Scl-Ab-treated mice, the serum concentration of TRAP5b was decreased compared to vehicle-treated animals, suggesting that Scl-Ab treatment activates bone formation and reduces bone resorption (Supplemental Figure 4A and B). This dual mode of action has been consistently reported in the context of the treatment of postmenopausal osteoporosis (13, 14) . To further investigate this finding at a cellular level, parameters of osteoblasts and osteoclasts were quantified in cancer-bearing mice.
As expected, the number and size of bone-forming osteoblasts was significantly increased in Scl-Ab-treated cancer-bearing mice compared to vehicle-treated control animals ( Figure 3 , H and I).
Furthermore, the number and size of bone-resorbing osteoclasts was strongly reduced in response to Scl-Ab treatment ( Figure 3 , J and K), suggesting that the increase in bone mass was due to a concomitant increase in bone formation and a reduction of bone resorption. Together, these data strongly indicate that Scl-Ab treatment does not only increase bone mass through its anabolic action by restoring the tumor-induced impairment of osteoblast function, but also reduces the breast cancer-mediated increase in osteoclast activity, thereby reverting osteolytic disease.
Inhibition of sclerostin prevents breast cancer-induced loss of muscle function
Patients with bone metastases often suffer from muscle weakness (17, 18) . Similarly, mice with breast cancer-induced metastatic bone disease have a reduced ex vivo muscle contractility compared to healthy animals ( Figure 4A ) (17) . Given the beneficial effect of Scl-Ab in reducing tumor burden and bone destruction, we postulated that inhibition of sclerostin might also affect muscle function. To test this hypothesis, we analyzed the specific muscle force and endurance of Figure 4D ), it appears to be likely that metastatic bone disease may cause an oxidative stress and muscle fiber atrophy in skeletal muscles, which is prevented by treatment with Scl-Ab.
Antagonizing sclerostin restores breast cancer-induced increase of NF-κB signaling
To further elucidate the molecular mechanisms underlying the effect of Scl-Ab on skeletal muscles of cancer-bearing mice, we investigated various signaling pathways involved in oxidative stress.
Western blot analysis revealed an increased phosphorylation of p38, ERK1/2 and STAT3 in the gastrocnemius (GAS) muscle of cancer-bearing mice compared to healthy control animals ( Figure   5A , Supplemental Figure 5A ). Interestingly, the cancer-induced phosphorylation of p38 was restored in the muscles of Scl-Ab-treated animals ( Figure 5A ). Since activation of the NF-κB pathway has been shown to be a critical component of skeletal muscle atrophy (28), we investigated whether NF-κB signaling is also implicated in breast cancer-induced bone metastases. Under steady-state conditions, NF-κB is sequestered in the cytoplasm through an interaction with members of IκB family of inhibitor protein termed IκBs (Inhibitor of κB). Upon activation, the IKK complex, which contains the two IκB kinases IKKα and IKKβ, phosphorylates the IκB proteins thereby targeting them to ubiquitination and proteasomal degradation (28) . Interestingly, IKKα and IKKβ were strongly phosphorylated in the muscles of cancer-bearing mice treated with vehicle compared to healthy animals. Furthermore, phosphorylation of the NF-κB subunit p65 was strongly increased in cancer-bearing mice, indicating an activated NF-κB signaling.
Phosphorylation of IKKα, IKKβ and p65 was greatly reduced by Scl-Ab treatment ( Figure 5A ),
suggesting that the presence of breast cancer bone metastases activates the p38-NF-κB signaling cascade, which is attenuated by the inhibition of sclerostin.
myoblasts, we stimulated C2C12 myoblasts with recombinant sclerostin. Sclerostin treatment did not induce phosphorylation of p38 or the components of the NF-κB pathway (Supplemental Figure   5B , data not shown), suggesting that the pathway is activated indirectly by cytokines present in the metastatic micro-environment. TGF-1 is an abundant growth factor released from the bone matrix during breast cancer-induced bone resorption. Interestingly, stimulation of undifferentiated C2C12 myoblasts with TGF-1 activated the p38-NF-κB pathway, thus recapitulating the effect observed in the muscles of cancer-bearing mice ( Figure 5B ). Inhibition of the NF-κB pathway abrogated the TGF-1-induced phosphorylation of p38 ( Figure 5C ), suggesting that the effect of TGF-1 is at least in part mediated via NF-κB. Consistently, TGF-1 stimulation inhibited the differentiation of C2C12 myoblasts into myocytes as determined by a reduced expression of Myogenin and MyoD ( Figure 5D ). These data suggest that TGF-1 released from the bone matrix during osteolytic bone resorption reduces muscle function, which is prevented by Scl-Ab treatment. Indeed, the expression of the TGF-1 target gene Pai1 was significantly increased in muscles of bone metastases-bearing mice compared to healthy animals ( Figure 5E ). However, Pai1 expression was not increased in the muscles of Scl-Ab-treated tumor-bearing mice ( Figure 5E ), indicating that Scl-Ab treatment restores the breast cancer-induced activation of the TGF-1 and p38-NF-κB pathway.
In colon cancer, NF-κB accumulation prevents the downregulation of Pax7, leading to a compromised muscle regeneration and impaired skeletal muscle function (29) . To address the question whether this also occurs in mice with breast cancer bone metastases, we analyzed the number of Pax7-positive satellite cells in the tibialis anterior muscles. Interestingly, the number of Pax7-positive cells was significantly increased in cancer-bearing mice compared to healthy animals ( Figure 5 , F and G). This cancer-induced increase was partially but significantly restored by SclAb treatment ( Figure 5G ). Together, these data suggest that pharmacological inhibition of sclerostin protects from breast cancer-induced loss of muscle function by preventing the cancermediated activation of NF-κB signaling and the subsequent increase of Pax7-positive satellite cells.
Discussion
In the present study we report that MDA-MB-231 metastatic breast cancer cells secrete sclerostin, a soluble glycoprotein that binds to Lrp5/6 on osteoblasts and prevents the activation of the Lrp5/6-frizzled receptor complex by soluble Wnt ligands and subsequent activation of the canonical Wnt signaling pathway (11) . In vitro assays revealed that metastatic breast cancer cell-derived sclerostin restricts osteoblast differentiation. In vivo inhibition of sclerostin using a monoclonal antisclerostin antibody (Scl-Ab) reduced bone metastatic burden and protected from breast cancerinduced bone destruction. At the tissue level, inhibition of sclerostin increased the bone formation rate and bone mass in both healthy and cancer-bearing mice. In mice with bone metastases, sclerostin inhibition increased the osteoblast number and the bone formation rate, while the number and activity of osteoclasts was decreased. Together these effects restricted the tumor burden and osteolytic bone destruction, thereby increasing the survival time of cancer-bearing mice.
Muscle weakness is known to accompany metastatic breast cancer disease (17, 30) Patients with advanced metastatic breast cancer often suffer from a wasting condition in which skeletal muscle undergoes atrophy, leading to a pronounced weight loss and ultimately cachexia (39, 40) . In the muscle micro-environment, Pax7-positive satellite cells are the main resident stem cells that can give rise to myocytes (41) . In addition, other interstitial and perivascular cell populations can also enter the myogenic lineage and contribute to muscle repair in response to tissue damage (42) . Muscle damage can be a consequence of cachexia that is associated with an expansion and activation of Pax7-positive interstitial satellite cells and type 2 fiber atrophy (43).
Satellite cell activation is indicated by an increased abundance of desmin and phospho-p38α (44).
Under normal conditions, satellite cells are positioned between the myofiber sarcolemma and the basal lamina, but exit from quiescence upon muscle damage along with other myogenic progenitor populations and subsequently expand as myoblasts to repair damaged fibers (45) . Perturbation of the sarcolemma and the basal lamina as well as satellite cell activation in cachectic muscle is not due to the spreading of tumor cells but rather caused by circulating factors including TGF-1 (17).
Serum-derived cachectic factors activate NF-κB signaling in myogenic progenitors upstream of Pax7, which becomes upregulated and suppresses the expression of MyoD and myogenin. This mechanism blocks myogenic differentiation, myoblast fusion and promotes muscle wasting (29) .
Furthermore, it has been demonstrated that the increase of circulating TGF-1 in the context of osteolytic disease upregulated the NADPH oxidase 4 in skeletal muscle, causing an oxidation of the ryanodine receptor and calcium (Ca 2+ ) release channel (RyR1) (17) . Oxidation of RyR1 leads to Ca 2+ leakage and an impairment of muscle contraction (17) . These findings strongly indicate that several molecular mechanisms exist that contribute to a cancer and bone metastases-mediated decline of muscle function and ultimately cachexia.
In the present study, we report that mice with breast cancer bone metastases have a reduced muscle strength and endurance and demonstrate that the muscle weakness is fully abrogated by a treatment with Scl-Ab. Our data are consistent with the findings reported by others and demonstrate that advanced stages of malignancy and bone metastases cause muscle weakness (17) . However, the therapeutic concept of sclerostin inhibition on muscle function has not been reported thus far and is of great clinical interest. At the tissue level, advanced malignancy with bone metastases caused a reduction of the size of oxidative and non-oxidative muscle fibers. Antagonizing sclerostin activity restored the muscle fiber atrophy, thereby normalizing the tissue micro-architecture.
Molecularly, cancer-induced muscle fiber atrophy was associated with an increased NF-κB and p38 signaling that was also induced by TGF-1 and normalized by Scl-Ab treatment. Stimulation with TGF-1 also reduced the myogenin expression and myoblast differentiation. These findings suggest that the enhanced osteoclast activity in the bone-cancer micro-environment increases the serum concentration of bone matrix-derived TGF-1, impairs myogenin expression and muscle regeneration downstream of NF-κB and p38 signaling. Indeed, the TGF-1 pathway activity was increased in the muscle tissue evidenced by an increased Pai-1 expression, which was at least in part reconstituted by sclerostin inhibition. Furthermore, the number of Pax7-positive satellite cells was strikingly increased in tumor-bearing mice and almost normalized by the Scl-Ab treatment.
We therefore propose that the bone-forming effect and the anti-resorptive properties of the anti- 
Methods
Animal experiments. MDA-MB-231 breast cancer cells stably expressing the luciferase gene were described elsewhere (46) Micro-computed tomography. Micro-computed tomography (µCT) was used for three dimensional analyses of long bones. Long bones of mice were analyzed using high-resolution µCT with a fixed isotropic voxel size of 10 µm (70 peak kV at X μA 400 ms integration time; Viva80 micro-CT; Scanco Medical AG). All analyses were performed on the digitally extracted bone tissue using 3D distance techniques (Scanco Medical AG) as reported previously (47) . Region of interest (ROI) was defined manually by drawing contours in slices. Due to cancer-induced bone destruction and absence of intact bone surfaces in cancer-bearing mice, the ROI contained both the cortical and the trabecular bone. In non-cancer-bearing bones only trabecular bone was analyzed using a standard method (47) .
Ex vivo analysis of muscle function. Ex vivo contractility of the Extensor digitorum longus muscle
(EDL) was analyzed using a device dedicated to the measurement of mouse muscle properties in situ, ex vivo and in vivo (Aurora Scientific). For this purpose, EDL was dissected from the hind limb, loops were tied to the tendons of the muscles and mounted to a force transducer. Muscles were stimulated to contract using a supramaximal stimulus applied by two electrodes. For fatigue studies, EDL was stimulated with 70 Hz for 50 repeats and the maximum tetanic force was detected. Data were collected and analyzed using Dynamic Muscle Control/Data acquisition (DMC) and Dynamic Muscle Control Data Analysis (DMA) programs (Aurora Scientific). Specific muscle force was calculated as described previously (48) . Investigators were blinded during data analysis.
Histological and immunohistochemical analyses. For bone analyses, mice were injected seven and two days prior to sacrifice with calcein (20 mg/kg) and demeclocycline (20 mg/kg; both SigmaAldrich), respectively. Tibiae were collected and fixed in 4% paraformaldehyde (PFA) for 48
hours. For histomorphometric analysis, tibiae were embedded in methylmethacrylate. Toluidine blue, von Kossa/van Gieson and Tartrate-resistant acid phosphatase (TRAP) staining were performed using 5 µm sagittal sections. Quantitative bone histomorphometric measurements were performed according to standard protocols using an OsteoMeasure system (Osteometrics) (49).
Femura were cleaned from soft tissue, fixed in 4% PFA for 24 hours at +4°C, decalcified with 4%
EDTA for 4 days and 20% EDTA for 24 hours and embedded in paraffin. Sections were cut and immuno-histochemical staining was performed using an anti-Osterix antibody (Rabbit polyclonal; Santa Cruz). Brain and lung tissues were fixed in 4% PFA for 24 hours at +4°C. Tissue samples were embedded in paraffin, cut and immuno-histochemical staining was performed with an antibody against HLA Class 1 ABC (Mouse monoclonal, Abcam).
For histological analyses of the muscle tissues, the tibialis anterior (TA) muscle was dissected from the hind limb, embedded in 10% Gum Tragacanth and snap-frozen in cooled 2-Methylbutane. Cryo sections were performed using a cryotome and sections were stained for succinate dehydroxygenase (SDH). Pax7 staining was performed using anti-Pax7 antibody (mouse monoclonal; Developmental Studies Hybridoma Bank (DSHB)). The muscle fiber area and the number of Pax7-positive cells were quantified using the Osteomeasure system (Osteometrics). The investigators were blinded regarding the treatment.
Cell culture. For calvarial osteoblast cultures, calvariae were dissected from 1 to 3-day old mice and digested sequentially in α-MEM containing 0.1% collagenase and 0.2% dispase (both Roche).
Cell fractions 2 to 4 were combined and expanded in α-MEM (Invitrogen) containing 10% Fetal Bovine Serum (FBS; Invitrogen) and 100 U/ml penicillin; 100 µg/ml streptomycin (Invitrogen). Immunoblotting. Cells were lysed in low salt lysis buffer (pH 7.6) containing 50 mM Tris base, 150 mM NaCl, 0,5% Nonindet P-40 (NP-40), 0,25% Sodium deoxycholate and complete protease and phosphatase inhibitors (Roche). Muscle tissue was homogenized in lysis buffer (20 mM Tris, pH 7.8, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% Triton X-100, 10% glycerol, 1 mM EDTA, 1 mM dithiothreitol and protease and phosphatase inhibitors) using a dounce homogenizer. Lysates were separated on 12% polyacrylamide gels and subjected to immunoblot analysis. Immunoblots were incubated over night at 4°C with primary antibodies listed in Table 2 . Peroxidase-labeled anti-rabbit or anti-mouse secondary antibodies (1:10 000, Santa Cruz, Cat. No: W401B, W402B)
were used to visualize bands using the Clarity Western ECL Substrate (BioRad). Images of the immunoblots were acquired using the ChemiDoc imaging system and Image Lab software (BioRad).
ELISA. Enzyme-linked immunosorbent assay (ELISA) was used to determine P1NP and TRAP concentration in the mouse serum. All procedures were performed according to the manufacturer's (immunodiagnostics systems) instructions.
Statistics. Parametric data were analyzed using a two-tailed Student´s t-test when two groups were compared. A one-way analysis of variance (ANOVA) was used when more than two groups were compared, followed by a Tukey's post-hoc analysis to compare the groups. Probability values were considered statistically significant at p<0.05. Experiments were repeated at least three times as biological replicates with minimum two technical replicates. All quantitative data are represented as mean ± SEM.
Study approval. All animal experiments were conducted in compliance with ethical regulations and according to the protocols approved by the local authority for animal welfare. (G) Wnt signaling activity in calvarial osteoblasts isolated from mice heterozygous for the LRP5 mutation G171V (LRP5-G171V +/T ) and from control littermates (LRP5-G171V +/+ ) stimulated with control medium or cancer CM (n=4 independent experiments). Data are represented as mean ± SEM. Two-tailed Student´s t-test was used to compare two groups (A, D), and ANOVA followed by Tukey's post-hoc analysis was used to compare three or more groups (C, E, F), *p<0.05, **p<0.01, ***p<0.001. of all muscle fibers, oxidative fibers (dark) and non-oxidative (light) fibers using SDH-stained muscle sections from healthy mice without treatment (n=5), vehicle (n=10) or Scl-Ab treatment (n=10) and from cancer-bearing mice treated with vehicle (n=8) or Scl-Ab (n=8). Data are represented as mean ± SEM. Three or more groups were compared using ANOVA followed by Tukey's post-hoc analysis, *p<0.05, **p<0.01, ***p<0.001. , phosphorylated NF-κBp65 (p-NF-κBp65), phosphorylated p38 (p-p38) and total p38 in the gastrocnemius (GAS) muscle of healthy non-treated mice (n=5) and cancer-bearing mice treated with vehicle (n=8) or Scl-Ab (n=8). Actin was used as loading control. Representative samples are shown. (B) Immunoblot analysis of phosphorylated NF-κBp65 (p-NF-κBp65), phosphorylated p38 (pp38) and total p38 in C2C12 myoblasts stimulated with vehicle (veh) or TGF-1. Actin was used as loading control. Representative image of 6 independent experiments is shown. (C) Immunoblot analysis of phosphorylated NF-κBp65 (p-NF-κBp65), phosphorylated p38 (p-p38) and total p38 in C2C12 cells treated with a control peptide or an NF-κB blocking peptide (NPD) and stimulated with vehicle or TGF-1. Actin was used as loading control. Representative image of 4 independent experiments is shown (D) Myogenin and MyoD mRNA expression was quantified by qRT-PCR in C2C12 cells after 10 days of myogenic differentiation (n=3). (E) Pai1 mRNA expression was quantified in the GAS muscle from healthy non-treated mice (n=5) and from cancer-bearing mice treated with vehicle (n=8) or Scl-Ab (n=8). (F) Immuno-histochemical staining of Pax7 in the TA muscle from healthy nontreated mice and from mice with bone metastases treated with vehicle or Scl-Ab. Scale bar indicates 50 µm in the upper panel and 100 µm in the lower panel. (G) Quantification of Pax7-positive cells in the TA muscle from healthy non-treated mice (n=5) and from mice with bone metastases treated with vehicle (n=8) or Scl-Ab (n=8). Data are represented as mean ± SEM. Two-tailed Student´s t-test was used to compare two groups (C), and ANOVA followed by Tukey's post-hoc analysis was used to compare three or more groups (D, F), *p<0.05, ***p<0.001. 
